Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions.
사설/논평
0/5 보강
APA
Rezaee-Zavareh MS, Yang JD (2026). Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions.. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70551
MLA
Rezaee-Zavareh MS, et al.. "Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions.." Alimentary pharmacology & therapeutics, 2026.
PMID
41795133 ↗
같은 제1저자의 인용 많은 논문 (4)
- Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma.
- Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis.
- Liver transplantation for hepatocellular carcinoma: from patient selection and downstaging to risk stratification and post-transplant surveillance.
- Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.